Status:
COMPLETED
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Lead Sponsor:
TCR2 Therapeutics
Conditions:
Non Hodgkin Lymphoma
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit whic...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient is \> 18 years of age at the time the Informed Consent is signed
- Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU
- Histologically confirmed NHL or ALL
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Patient must have adequate organ function as indicated by the laboratory values in the clinical protocol
- Patient must be fit for leukapheresis and have adequate venous access for cell collection
- Patient must have evidence of CD19 expression
- Prior CD19-directed CAR T therapy is allowed
Exclusion
Key Trial Info
Start Date :
March 27 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 24 2023
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04323657
Start Date
March 27 2020
End Date
February 24 2023
Last Update
March 16 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
2
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
3
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030